New Zealand Data Sheet - Medsafe
3 | Page 4.8. Undesirable effects The safety of ketoconazole 2% shampoo was evaluated in 2890 subjects who participated in 22 clinical trials.
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Prescriber Dosing and Management Checklist …
www.qsymiarems.comPrescriber Dosing and Management Checklist Qsymia®® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
Management, Checklist, Dosing, Prescriber, Prescriber dosing and management checklist
Hepatic Diet - Regional Digestive Consulting
www.regionaldigestiveconsultants.com1 | P a g e Hepatic Diet Hepatic diets are indicated for individuals with symptoms of hepatic dysfunction such as cirrhosis, liver injury, hepatic failure and
RxFiles Krahn UofS Regier URGENCY …
www.rxfiles.caRxFiles Q&A Summary www.RxFiles.ca ‐ updated June 2016 K Krahn UofS BSP Student 2014, L Regier BSP, BA HYPERTENSIVE URGENCY(ASYMPTOMATIC SEVERE HYPERTENSION): CONSIDERATIONS FOR MANAGEMENT Hypertension is oneof themost common chronic medicalconditions inCanada. Morethan five …
Considerations, Severe, Hypertension, Asymptomatic severe hypertension, Asymptomatic, Considerations for
DOSAGE FORMS AN - Venofer
www.venofer.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VENOFER safely and effectively. See full prescribing information for VENOFER.
Reference ID: 3101735
www.accessdata.fda.govFULL PRESCRIBING INFORMATION WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION The incidence of treatment-related mortality associated with docetaxel therapy is
[Product Monograph Template - Standard] - …
www.medunikcanada.comPheburane Product Monograph Page 1 of 24 . PRODUCT MONOGRAPH . PrPheburane®. Sodium phenylbutyrate granules . 483 mg per gram of granules . ATC Code: A16AX03 . Alimentary tract and metabolism product